

## Key investor information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

### ABANTE BIOTECH FUND, a sub-fund of ABANTE GLOBAL FUNDS

#### Class C USD (Accumulation) LU1894892188

Management Company: Abante Asesores Gestion SGIIC, S.A.

### Objectives and investment policy

The investment objective is to preserve capital and achieve long-term capital growth primarily by investing throughout the biotechnology sector, across geographies and market capitalisations. North America, NASDAQ and small and mid-capitalized companies will be respectively the main geography, market and capitalisation focus of the sub-fund.

There is however no guarantee that this objective will be achieved.

Investment decisions are made by a dedicated team of experienced professionals (the Managers) with relevant scientific and financial backgrounds. The managers employ a bottom-up, research-intensive investment approach including scientific (clinical data), financial due diligence and fundamental valuation assessment.

The sub-fund will invest in a diversified portfolio of stocks (typically above 20) that have met all the selection criteria following the managers investment style.

At least 70% of the total assets of the sub-fund shall be invested in equity or equity related instruments of North America, Western Europe, Japan, Israel, South Korea, Hong Kong and Australia. Given the particularly innovative nature of the industry in North America, the majority of investments will be made in this zone.

The net assets of the sub-fund will be mainly invested in small and medium caps (<5,000,000,000\$).

Up to 30% of the total assets of the sub-fund may be invested in aggregate in cash and cash equivalents.

Up to 30% of the total assets of the Sub-Fund may be invested in aggregate in stocks out of the biotechnology space but into the healthcare.

Subject to Part A Chapter I section C "Investment Restrictions", the sub-fund may not invest more than 10% of its assets in other UCITS and other UCIs.

The sub-fund may use financial derivative instruments for hedging and investment Purposes.

Recommendation: this sub-fund may not be appropriate for investors who plan to withdraw their money within 3-5 years.

Shareholders may redeem shares on demand, on each Business day.

Non-distribution shares: any income generated by the sub-fund is reinvested.

Please note that transaction costs may have material impact on performance.

### Risk and reward profile



Historical data used may not be a reliable indication of the future risk profile of the sub-fund.

This category is not guaranteed to remain unchanged and may shift over time.

The lowest category does not mean a risk-free investment.

This indicator is based on the historical volatility of the reference portfolio over the past 5 years and places the sub-fund in this category.

Due to a lack of sufficient historical data, the risk indicator incorporates simulated data from a benchmark portfolio. Risk Category 7 reflects the highest potential gains and/or losses for the portfolio. This is due to investments in international equities of small and mid-capitalized companies mainly on the north american market.

The risk category has been determined using the maximum risk limit allowed for this sub-fund.

**The following risks may be materially relevant and may not be adequately captured by the synthetic risk indicator:**

**Currency risk:** the risk that an investment's value will be affected by changes in exchange rates.

**Use of derivatives:** derivatives are used for investment purposes and contribute to obtain, increase or reduce exposure to underlying assets.

**Equity risk:** the value of equities and equity-related securities can be affected by daily stock market movements.

## Charges

The charges you pay are used to pay the costs of running the sub-fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	None
Exit charge	None
This is the maximum that might be taken out of your money before it is invested / before the proceeds of your investment are paid out.	
Charges taken from the fund over a year	
Ongoing charges	1.55%
Charges taken from the fund under specific conditions	
Performance fee	No performance fees for the sub-fund's last financial year.
9% of the performance of the NAV per Share exceeding the high water mark	

The **entry charge** shown is a maximum figure. In some cases you might pay less; you can find this out from your sales agent or financial advisor.

The indicated **ongoing charges** figure is an estimate based on the expected total amount of charges. The next annual report of the fund will include details on the exact charges taken from the sub-fund. This figure may vary from year to year.

**For more information about charges, please refer to the fund's prospectus available at the registered office of the fund and on the following website: [www.abanteasesores.com](http://www.abanteasesores.com).**

## Past performance

Regulations state that only subscribed share classes or share classes with a past performance history greater than 12 months can be shown.


Past performance should not be considered an indicator of future performance.

There is insufficient data to provide a useful indication of past performance.

The sub-fund was launched on 30 November 2018

The Class was launched on 22 March 2019

The currency of the Class is the US Dollar.



## Practical information

The Depositary of the fund is Edmond de Rothschild (Europe)

Copies of the prospectus and the last annual and semi-annual reports of the entire fund as well as other practical information such as the latest price for the shares may be obtained free of charge, in English, at the registered office of the fund: 20, boulevard Emmanuel Servais, L-2535 Luxembourg, Grand Duchy of Luxembourg and on the following website: [www.abanteasesores.com](http://www.abanteasesores.com).

The details of the up-to-date remuneration policy of the Management Company, including, but not limited to a description of how remuneration and benefits are calculated, the identity of the persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee, where such a committee exists, are available at <http://www.abanteasesores.com>. A paper copy of the summarized remuneration policy is available free of charge to the shareholders upon request.

The tax legislation in Luxembourg may have an impact on your personal tax position.

The assets and liabilities of each sub-fund of ABANTE GLOBAL FUNDS are segregated. The assets of any particular sub-fund will only be available to satisfy the debts, liabilities and obligations which relate to that sub-fund.

You have the right to convert your investment in the sub-fund for shares of the same Class of another sub-fund of ABANTE GLOBAL FUNDS under the conditions described in the fund's prospectus.

Abante Asesores Gestion SGIIC, S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.

This sub-fund is authorised in Luxembourg and supervised by the CSSF.

Abante Asesores Gestion SGIIC, S.A. is authorised in Luxembourg and regulated by the CNMV.

This key investor information is accurate as at 22 March 2019.